Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Fagotti

Showing results (121-130 of 571) with videos related to

Pageof 58
Sort By:
Annals of Surgical Oncology|June 4, 2015
Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control StudyMarco Petrillo, Ida Paris, Giuseppe Vizzielli, et al.
Journal of Minimally Invasive Gynecology|January 19, 2016
Laparoscopic Splenectomy for Secondary Cytoreduction in Ovarian Cancer Patients With Localized Spleen Recurrence: Feasibility and TechniqueValerio Gallotta, Camilla Nero, Claudio Lodoli, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|June 14, 2025
In-transit metastatic lymph nodes in cervical cancer: A new staging and therapeutic conceptMatteo Pavone, Nicolò Bizzarri, Agnieszka Rychlik, et al.
Anticancer Research|December 6, 2015
Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent Ovarian Cancer?Francesco Fanfani, Anna Fagotti, Alfredo Ercoli, et al.
Expert Opinion on Investigational Drugs|January 11, 2021
Oregovomab: an investigational agent for the treatment of advanced ovarian cancerAntonella Pietragalla, Simona Duranti, Gennaro Daniele, et al.
Gynecologic Oncology|May 6, 2011
HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcomeAnna Fagotti, Barbara Costantini, Giuseppe Vizzielli, et al.
Annals of Surgical Oncology|June 2, 2026
Predictive Features Specific to FIGO IIIA1 Ovarian Cancer: What Drives PrognosisMatteo Bruno, Davide Arrigo, Marco Paratore, et al.
Annals of Surgical Oncology|June 14, 2026
ASO Visual Abstract: Predictive Features Specific to FIGO IIIA1 Ovarian Cancer: What Drives PrognosisMatteo Bruno, Davide Arrigo, Marco Paratore, et al.
Molecular Biology Reports|March 3, 2021
The BRCA1 c.788G > T (NM_007294.4) variant in a high grade serous ovarian cancer (HGSOC) patient: foods for thoughtElisa De Paolis, Antonella Pietragalla, Maria De Bonis, et al.
Gynecologic Oncology|February 22, 2005
Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot studyAnna Fagotti, Francesco Fanfani, Manuela Ludovisi, et al.
Pageof 58

Showing results (121-130 of 571) with videos related to

Sort By:
Pageof 58
Annals of Surgical Oncology|June 4, 2015
Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control StudyMarco Petrillo, Ida Paris, Giuseppe Vizzielli, et al.
Journal of Minimally Invasive Gynecology|January 19, 2016
Laparoscopic Splenectomy for Secondary Cytoreduction in Ovarian Cancer Patients With Localized Spleen Recurrence: Feasibility and TechniqueValerio Gallotta, Camilla Nero, Claudio Lodoli, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|June 14, 2025
In-transit metastatic lymph nodes in cervical cancer: A new staging and therapeutic conceptMatteo Pavone, Nicolò Bizzarri, Agnieszka Rychlik, et al.
Anticancer Research|December 6, 2015
Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent Ovarian Cancer?Francesco Fanfani, Anna Fagotti, Alfredo Ercoli, et al.
Expert Opinion on Investigational Drugs|January 11, 2021
Oregovomab: an investigational agent for the treatment of advanced ovarian cancerAntonella Pietragalla, Simona Duranti, Gennaro Daniele, et al.
Gynecologic Oncology|May 6, 2011
HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcomeAnna Fagotti, Barbara Costantini, Giuseppe Vizzielli, et al.
Annals of Surgical Oncology|June 2, 2026
Predictive Features Specific to FIGO IIIA1 Ovarian Cancer: What Drives PrognosisMatteo Bruno, Davide Arrigo, Marco Paratore, et al.
Annals of Surgical Oncology|June 14, 2026
ASO Visual Abstract: Predictive Features Specific to FIGO IIIA1 Ovarian Cancer: What Drives PrognosisMatteo Bruno, Davide Arrigo, Marco Paratore, et al.
Molecular Biology Reports|March 3, 2021
The BRCA1 c.788G > T (NM_007294.4) variant in a high grade serous ovarian cancer (HGSOC) patient: foods for thoughtElisa De Paolis, Antonella Pietragalla, Maria De Bonis, et al.
Gynecologic Oncology|February 22, 2005
Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot studyAnna Fagotti, Francesco Fanfani, Manuela Ludovisi, et al.
Pageof 58